Reports

Drug name	NICE TAs	Comments
Betamethasone valerate 0.025% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate RD. Moderate potency.
Betamethasone valerate 0.025% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate RD. Moderate potency.
Betamethasone valerate 0.1% cream	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betaxolol eye drops		Specialist ophthalmologist recommendation 0.25% ophthalmic suspension 0.5% eye drops 0.5% unit dose eye drops
Bevacizumab infusion (Avastin®)	TA178 - Bevacizumab (first-line), sorafenib (first and second line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA285 - Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	Negative NICE TA & hospital use only.
Biotene oralbalance saliva replacement gel		Approved for ACBS conditions e.g. dry mouth (Xerostomia) as a result of (or having undergone) radiotherapy, or sicca syndrome. Palliative care, dental practitioners.
Bivalirudin 250mg injection		Hospital use only
Bleomycin injection		Hospital use only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports